琥珀酸索利那新在控制经尿道膀胱肿瘤电切术后膀胱刺激症状中的价值

目的 探讨索利那新在控制经尿道膀胱肿瘤电切术后膀胱刺激症状中的价值.方法 116例诊断为非肌层浸润性膀胱癌的患者纳入本研究,患者被随机分为试验组和对照组.所有患者均接受经尿道膀胱肿瘤电切术和术后即刻表柔比星灌注治疗;试验组患者于术前6h和术后连续3d每天口服索利那新5mg,对照组患者口服安慰剂;于术后6、12、24、48和72 h分别记录膀胱刺激症状评分.结果 膀胱刺激症状的发生率从93.1％(对照组)下降到67.2％(试验组)(P=0.001);在各个观测时间点对照组膀胱刺激症状的严重性均高于试验组(P＜0.05或P＜0.01).结论 索利那新可有效改善经尿道膀胱肿瘤电切术后膀胱刺激症状.

Solifenacin succinate in improving bladder irritative symptoms after transurethral resection of bladder tumors

Objective To explore the value of solifenacin in managing bladder irritative symptoms after transurethral resection of bladder tumor. Methods A total of 116 patients with the diagnosis of non-muscle invasive bladder carcinoma were enrolled in the present study, and they were randomly allocated into experiment group and control group. All patients received transurethral resection of bladder cancer and immediate postoperative instillation of epirubicin. Patients in the experiment group also received solifenacin 5 mg at 6 h before surgery and once a day after surgery for 3 d, while the patients in the control group received placebo. The incidences and severity of catheter related bladder discomfort were recorded at 6, 12, 24, 48 and 72 h after surgery. Results The incidence rate of bladder irritative symptoms significantly decreased from 93.1% in the control group to 67.2% in the experiment group(P=0.001). Compared with the control group, the severity of bladder irritative symptoms in the experiment group was significantly improved at all time points (P<0.05 or P<0.01). Conclusion Solifenacin is effective for managing bladder irritative symptoms after transurethral resection of bladder tumors.